Crossmark

A Novel Second-Generation EP2 Receptor Antagonist Reduces Neuroinflammation and Gliosis After Status Epilepticus in Rats

Crossref DOI link: https://doi.org/10.1007/s13311-020-00969-5

Published Print: 2021-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Rojas, Asheebo

Amaradhi, Radhika

Banik, Avijit

Jiang, Chunxiang

Abreu-Melon, JuanMartin

Wang, Sarah

Dingledine, Raymond

Ganesh, Thota
Funding

Funding for this research was provided by:

National Institute on Aging (AG052460)

National Institute of Neurological Disorders and Stroke (NS101167)

National Institute of Neurological Disorders and Stroke (NS097776)

National Institute of Neurological Disorders and Stroke (NS112308)
License Information

Text and Data Mining valid from 2021-04-01

Text and Data Mining valid from 2021-04-01

Version of Record valid from 2023-08-18
More Information

This article is maintained by: Elsevier

Article Title: A Novel Second-Generation EP2 Receptor Antagonist Reduces Neuroinflammation and Gliosis After Status Epilepticus in Rats

Journal Title: Neurotherapeutics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1007/s13311-020-00969-5

Content Type: article

Copyright: Copyright © 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.